Psilocybin research is no longer just for hard-to-treat cases - a new trial targeted recurrent depression in people who had not failed standard treatment, and the results are promising
Space Daily • • health
Key Points:
- A new trial from Karolinska Institutet studied psilocybin's effects on 35 participants with recurrent depression, a larger and less treatment-resistant population than prior research typically focused on.
- Participants received either a single 25 mg dose of psilocybin or a placebo, alongside psychological support, with follow-up lasting a full year to assess lasting effects.
- Results showed rapid mood improvements by day eight in the psilocybin group, with over half no longer meeting clinical depression criteria at six weeks, outperforming placebo significantly in early phases.
- The study highlights psilocybin’s potential as a faster-acting treatment for recurrent depression, which could reduce the duration of depressive episodes and shift treatment paradigms away from daily medication.
- Limitations include the small sample size, challenges with blinding due to psilocybin’s unmistakable effects, and some adverse reactions; larger trials and regulatory frameworks are needed before clinical adoption.